tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TAK Stock Latest News

Takeda’s New South Korea HAE Study Aims to Cement Takhzyro’s Real World Edge
Company AnnouncementsTakeda’s New South Korea HAE Study Aims to Cement Takhzyro’s Real World Edge
2d ago
TAK
Takeda’s EXPLORHAE HAE Study in Egypt: Real‑World Data With Long‑Term Investor Upside
PremiumCompany Announcements
Takeda’s EXPLORHAE HAE Study in Egypt: Real‑World Data With Long‑Term Investor Upside
2d ago
TAK
Takeda Deepens Real-World Evidence in Ultra-Rare cTTP With New ADAMTS13 Study
PremiumCompany Announcements
Takeda Deepens Real-World Evidence in Ultra-Rare cTTP With New ADAMTS13 Study
2d ago
TAK
Takeda-Backed Phase 3 Lung Cancer Trial Pits Novel IBI363 Against Docetaxel
PremiumCompany Announcements
Takeda-Backed Phase 3 Lung Cancer Trial Pits Novel IBI363 Against Docetaxel
6d ago
TAK
Takeda’s TAK-861 Narcolepsy Study Moves Forward, Extending the Long-Term Bet on Sleep Disorders
PremiumCompany Announcements
Takeda’s TAK-861 Narcolepsy Study Moves Forward, Extending the Long-Term Bet on Sleep Disorders
10d ago
TAK
Takeda Advances Fazirsiran Phase 3 Liver Study, Keeping Rare-Disease Growth Story in Play
PremiumCompany AnnouncementsTakeda Advances Fazirsiran Phase 3 Liver Study, Keeping Rare-Disease Growth Story in Play
10d ago
TAK
Takeda Maps Narcolepsy in Spain: What This New Epidemiology Study Means for Investors
Premium
Company Announcements
Takeda Maps Narcolepsy in Spain: What This New Epidemiology Study Means for Investors
10d ago
TAK
Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
Premium
The Fly
Protagonist Therapeutics price target raised to $100 from $86 at Wedbush
13d ago
TAK
PTGX
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
PremiumThe Fly
Takeda, Protagonist announce FDA acceptance of rusfertide new drug application
13d ago
TAK
PTGX
Takeda Expands Fruquintinib Data With New Minority-Focused Colorectal Cancer Study
PremiumCompany Announcements
Takeda Expands Fruquintinib Data With New Minority-Focused Colorectal Cancer Study
16d ago
TAK
Takeda Tracks Real-World Safety of Fruzaqla in South Korean Colorectal Cancer Patients
PremiumCompany Announcements
Takeda Tracks Real-World Safety of Fruzaqla in South Korean Colorectal Cancer Patients
16d ago
TAK
Takeda Expands Real-World Evidence for Takhzyro With New Saudi Arabia HAE Study
PremiumCompany Announcements
Takeda Expands Real-World Evidence for Takhzyro With New Saudi Arabia HAE Study
18d ago
TAK
Takeda’s Paediatric HAE Study Strengthens Real-World Case for Takhzyro
PremiumCompany AnnouncementsTakeda’s Paediatric HAE Study Strengthens Real-World Case for Takhzyro
18d ago
TAK
Boston Scientific names Cathy Smith, Christophe Weber to board of directors
Premium
The Fly
Boston Scientific names Cathy Smith, Christophe Weber to board of directors
20d ago
BSX
TAK
Takeda Targets Infection Risk in Multiple Myeloma With New Gammagard Phase 3 Study
Premium
Company Announcements
Takeda Targets Infection Risk in Multiple Myeloma With New Gammagard Phase 3 Study
23d ago
TAK
Takeda’s Cuvitru Safety Study: What a New Japanese Registry Update Means for TAK Investors
PremiumCompany Announcements
Takeda’s Cuvitru Safety Study: What a New Japanese Registry Update Means for TAK Investors
23d ago
TAK
Takeda’s Livmarli Safety Study in Japan: What Investors Should Watch in Rare Liver Disease
PremiumCompany Announcements
Takeda’s Livmarli Safety Study in Japan: What Investors Should Watch in Rare Liver Disease
23d ago
TAK
Takeda Advances Elritercept Into Phase 3, Targeting a New Edge in Anemia Care for MDS
PremiumCompany Announcements
Takeda Advances Elritercept Into Phase 3, Targeting a New Edge in Anemia Care for MDS
23d ago
TAK
Takeda announces data from Phase 3 KEPLER trial of ENTYVIO
PremiumThe Fly
Takeda announces data from Phase 3 KEPLER trial of ENTYVIO
24d ago
TAK
Takeda’s New Stroke Trial Adds Long-Term Optionality to TAK’s Pipeline
PremiumCompany AnnouncementsTakeda’s New Stroke Trial Adds Long-Term Optionality to TAK’s Pipeline
25d ago
TAK
Takeda’s HyQvia Study Tracks Real-World Use in Multiple Myeloma, Offering Gradual Upside for TAK Investors
Premium
Company Announcements
Takeda’s HyQvia Study Tracks Real-World Use in Multiple Myeloma, Offering Gradual Upside for TAK Investors
25d ago
TAK
Takeda Targets Better Hereditary Angioedema Diagnosis With New AHAE Study
Premium
Company Announcements
Takeda Targets Better Hereditary Angioedema Diagnosis With New AHAE Study
25d ago
TAK

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >